UK Markets closed

Grifols, S.A. (GRF.MC)

MCE - MCE Delayed price. Currency in EUR
Add to watchlist
20.50-0.13 (-0.63%)
At close: 5:35PM CEST
Full screen
Previous close20.63
Bid20.52 x 0
Ask20.54 x 0
Day's range20.38 - 20.81
52-week range19.18 - 26.94
Avg. volume813,562
Market cap12.062B
Beta (5Y monthly)0.10
PE ratio (TTM)25.00
EPS (TTM)0.82
Earnings date30 Jul 2021 - 09 Aug 2021
Forward dividend & yield0.36 (1.61%)
Ex-dividend date03 Jun 2021
1y target est25.56
  • Bloomberg

    Grifols Buys Biotest as Creat Pushed to Exit Blood-Plasma Stakes

    (Bloomberg) -- Grifols SA agreed to buy Biotest AG for about 1.6 billion euros ($1.9 billion), pouncing after U.S. regulators pushed back on Chinese shareholder Creat Group Corp.’s expansion into the blood-plasma industry.Grifols offered 43 euros for each ordinary share and 37 euros for each preferred share, the Spanish company said Friday. That’s 23% and 4.2% higher than Thursday’s closing prices, respectively. Bloomberg News reported late Thursday that the deal was imminent.Creat’s strategy to

  • Reuters

    Spain's Grifols to buy rival Biotest for up to $1.9 billion

    MADRID (Reuters) -Spanish pharmaceuticals company Grifols proposed a 1.6 billion euro ($1.9 billion) takeover of its German rival Biotest on Friday, in a move to consolidate the plasma-based drug industry. Grifols said it had agreed with Tiancheng International Investment to buy the Hong Kong-based company's controlling stake in Biotest for 1.1 billion euros. The Barcelona-based company agreed to buy 89.88% of Biotest's ordinary shares that carry voting rights, but which represent only 44.54% of the company's capital, and a further 0.54% of capital in preferred shares that do not carry voting rights, from Hong Kong-based Tiancheng.

  • Zacks

    Moving Average Crossover Alert: Grifols (GRFS)

    Grifols (GRFS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.